Nov 12, 2019 / 04:45PM GMT
Evan David Seigerman - Crédit Suisse AG - Research Division - VP & Senior Equity Research Analyst
This is Evan Seigerman. I'm the senior large cap biotechnology analyst here at Crédit Suisse. And it's my pleasure to have Amgen joining us today. And from Amgen, we have CFO, Dave Meline; of course, Arvind Sood, the Head of IR. So thank you very much for joining us in Scottsdale.
And before we jump into questions, I want to hand it off to David and also congratulate him on his upcoming retirement. We're going to miss you.
David W. Meline - Amgen Inc. - Executive VP & CFO
Okay. Thank you very much, Evan, good morning. I'll just make a few comments before Q&A around Amgen.
So I think I would start with the fact that we've been positioning the company to enjoy long-term sustainable growth of the business. And most recently, the couple of newsworthy events that will continue to support that path are a couple of transactions that we announced. So the acquisition of Otezla from Celgene as well as the BeiGene
Amgen Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 12, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers